File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Inhibition of COX-2/PGE2/EP4 signaling protects against cell apoptosis during hypoxia/reoxygenation in H9C2 cardiomyocytes
Title | Inhibition of COX-2/PGE2/EP4 signaling protects against cell apoptosis during hypoxia/reoxygenation in H9C2 cardiomyocytes |
---|---|
Authors | |
Issue Date | 2016 |
Publisher | Federation of American Societies for Experimental Biology. The Journal's web site is located at http://www.fasebj.org/ |
Citation | The 2016 Annual Meeting of the American Society of Pharmacology and Experimental (ASPET) held in conjunction with the Experimental Biology 2016 (EB 2016) Meeting, San Diego, CA., 2-6 April 2016. In The FASEB Journal, 2016, v. 30 meeting abstracts, no. 939.7 How to Cite? |
Abstract | Myocardial infarction is a condition associated with significant mortality. Reperfusion therapy restores blood flow, it may also induce lethal tissue injury, known as ischemia-reperfusion injury (IRI) in clinical practice. Thus, exploring ways to control or attenuate IRI is of clinical interest for improving post-ischemic recovery. Cyclooxyenase-2 (COX-2) – which is induced during ischemia - is highly expressed at the site of recent acute myocardial infarction (Heart. 2004;90:440–443). Furthermore, the presence of COX-2 is positively correlated with progressively increased apoptosis which played a central role in the pathophysiology of IRI. However, whether there is causal link or underlying signaling cascade between ischemia-driven COX-2 expression and apoptosis in IRI is unclear. Thus, the present study aimed to investigate the molecular basis of potential cause-effect link between COX-2 expression and enhanced apoptosis during ischemia using rat origin cardiomyocytes (H9C2) subjected to hypoxia/reoxygenation (H/R, 6 hours hypoxia followed by 12 hours reoxygenation). The results showed that H/R significantly increased the protein expression of COX-2 (P<0.05 vs. Control), which was prevented by 2 hours pretreatment with Helenalin (NFkB inhibitor, at 10μM, P<0.05 vs. H/R) but not by pretreatment with SC-205346A [Hypoxia inducible factor alpha (HIF-1α) inhibitor, at 20μM]. This suggests that NFkB but not HIF-1α mediated the expression of COX-2 during H/R in H9C2 cardiomyocytes. Further, under the experimental setting, H/R induced H9C2 cells damage [evidenced by increased lactic acid dehydrogenase (LDH) leakage (marker of cell injury, P<0.05 vs. Control)] was concomitant with increased cleaved caspase-3 expression (marker of cell apoptosis, P<0.05 vs. Control) but no changes in the protein expressions of the anti-apoptotic Bcl-2 and pro-apoptotic Bax, suggesting that H/R induced caspase-3 dependent cell apoptosis which was independent of the intrinsic mitochondrial pathway. Pretreat the cells with NS398 (COX-2 selective inhibitor, at 10μM, 1 hour) or L161,982 [prostaglandin E receptor subtype 4 (EP4) selective antagonist, at 100nM, 1 hour] suppressed the H/R induced increases of LDH leakage and cleaved caspase-3 expression (P<0.05 vs. H/R), indicating that both COX-2 and EP4 mediated cell apoptosis during H/R. Given that prostaglandin E2 (PGE2) is a major metabolite of COX-2 and an endogenous ligand of EP4 receptor, H9C2 cardiomyocytes were exposed to exogenous PGE2 (from 5nM to 50μM, 18 hours) in a concentration dependent manner. As anticipated, PGE2, at a high concentration (50μM), significantly increased cellular injury as evidenced by enhanced LDH leakage (P<0.05 vs. Control). It is concluded that H/R may induce cardiomyocytes apoptosis via NFkB/COX-2/PGE2/EP4 signaling, which may serve as a novel target for anti-ischemic therapy. |
Persistent Identifier | http://hdl.handle.net/10722/230256 |
ISSN | 2023 Impact Factor: 4.4 2023 SCImago Journal Rankings: 1.412 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pang, L | - |
dc.contributor.author | Ma, H | - |
dc.contributor.author | Cai, Y | - |
dc.contributor.author | Irwin, MG | - |
dc.contributor.author | Xia, Z | - |
dc.date.accessioned | 2016-08-23T14:16:00Z | - |
dc.date.available | 2016-08-23T14:16:00Z | - |
dc.date.issued | 2016 | - |
dc.identifier.citation | The 2016 Annual Meeting of the American Society of Pharmacology and Experimental (ASPET) held in conjunction with the Experimental Biology 2016 (EB 2016) Meeting, San Diego, CA., 2-6 April 2016. In The FASEB Journal, 2016, v. 30 meeting abstracts, no. 939.7 | - |
dc.identifier.issn | 0892-6638 | - |
dc.identifier.uri | http://hdl.handle.net/10722/230256 | - |
dc.description.abstract | Myocardial infarction is a condition associated with significant mortality. Reperfusion therapy restores blood flow, it may also induce lethal tissue injury, known as ischemia-reperfusion injury (IRI) in clinical practice. Thus, exploring ways to control or attenuate IRI is of clinical interest for improving post-ischemic recovery. Cyclooxyenase-2 (COX-2) – which is induced during ischemia - is highly expressed at the site of recent acute myocardial infarction (Heart. 2004;90:440–443). Furthermore, the presence of COX-2 is positively correlated with progressively increased apoptosis which played a central role in the pathophysiology of IRI. However, whether there is causal link or underlying signaling cascade between ischemia-driven COX-2 expression and apoptosis in IRI is unclear. Thus, the present study aimed to investigate the molecular basis of potential cause-effect link between COX-2 expression and enhanced apoptosis during ischemia using rat origin cardiomyocytes (H9C2) subjected to hypoxia/reoxygenation (H/R, 6 hours hypoxia followed by 12 hours reoxygenation). The results showed that H/R significantly increased the protein expression of COX-2 (P<0.05 vs. Control), which was prevented by 2 hours pretreatment with Helenalin (NFkB inhibitor, at 10μM, P<0.05 vs. H/R) but not by pretreatment with SC-205346A [Hypoxia inducible factor alpha (HIF-1α) inhibitor, at 20μM]. This suggests that NFkB but not HIF-1α mediated the expression of COX-2 during H/R in H9C2 cardiomyocytes. Further, under the experimental setting, H/R induced H9C2 cells damage [evidenced by increased lactic acid dehydrogenase (LDH) leakage (marker of cell injury, P<0.05 vs. Control)] was concomitant with increased cleaved caspase-3 expression (marker of cell apoptosis, P<0.05 vs. Control) but no changes in the protein expressions of the anti-apoptotic Bcl-2 and pro-apoptotic Bax, suggesting that H/R induced caspase-3 dependent cell apoptosis which was independent of the intrinsic mitochondrial pathway. Pretreat the cells with NS398 (COX-2 selective inhibitor, at 10μM, 1 hour) or L161,982 [prostaglandin E receptor subtype 4 (EP4) selective antagonist, at 100nM, 1 hour] suppressed the H/R induced increases of LDH leakage and cleaved caspase-3 expression (P<0.05 vs. H/R), indicating that both COX-2 and EP4 mediated cell apoptosis during H/R. Given that prostaglandin E2 (PGE2) is a major metabolite of COX-2 and an endogenous ligand of EP4 receptor, H9C2 cardiomyocytes were exposed to exogenous PGE2 (from 5nM to 50μM, 18 hours) in a concentration dependent manner. As anticipated, PGE2, at a high concentration (50μM), significantly increased cellular injury as evidenced by enhanced LDH leakage (P<0.05 vs. Control). It is concluded that H/R may induce cardiomyocytes apoptosis via NFkB/COX-2/PGE2/EP4 signaling, which may serve as a novel target for anti-ischemic therapy. | - |
dc.language | eng | - |
dc.publisher | Federation of American Societies for Experimental Biology. The Journal's web site is located at http://www.fasebj.org/ | - |
dc.relation.ispartof | The FASEB Journal | - |
dc.title | Inhibition of COX-2/PGE2/EP4 signaling protects against cell apoptosis during hypoxia/reoxygenation in H9C2 cardiomyocytes | - |
dc.type | Conference_Paper | - |
dc.identifier.email | Cai, Y: caidavid@hku.hk | - |
dc.identifier.email | Irwin, MG: mgirwin@hku.hk | - |
dc.identifier.email | Xia, Z: zyxia@hkucc.hku.hk | - |
dc.identifier.authority | Irwin, MG=rp00390 | - |
dc.identifier.authority | Xia, Z=rp00532 | - |
dc.identifier.hkuros | 261569 | - |
dc.identifier.volume | 30 | - |
dc.identifier.issue | meeting abstracts | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 0892-6638 | - |